Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Sep

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Losing Weight and Breast Cancer Risk? The GLP-1 Question

TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer

FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer

NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer